-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Looking Into Candel Therapeutics's Return On Capital Employed
Looking Into Candel Therapeutics's Return On Capital Employed
Benzinga Pro data, Candel Therapeutics (NASDAQ:CADL) reported Q2 sales of $31 thousand. Earnings fell to a loss of $4.15 million, resulting in a 374.71% decrease from last quarter. In Q1, Candel Therapeutics brought in $31 thousand in sales but lost $874 thousand in earnings.
Why Is ROCE Significant?
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Candel Therapeutics posted an ROCE of -0.07%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Candel Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
For Candel Therapeutics, a negative ROCE ratio of -0.07% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
Upcoming Earnings Estimate
Candel Therapeutics reported Q2 earnings per share at $-0.3/share, which beat analyst predictions of $-0.41/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Benzinga Pro data, Candel Therapeutics (NASDAQ:CADL) reported Q2 sales of $31 thousand. Earnings fell to a loss of $4.15 million, resulting in a 374.71% decrease from last quarter. In Q1, Candel Therapeutics brought in $31 thousand in sales but lost $874 thousand in earnings.
Benzinga Pro Data,秋茄治療公司納斯達克(Tmall:CADL)公佈第二季度銷售額為3.1萬美元。利潤下降至虧損415萬美元,比上一季度下降了374.71%。在第一季度,Candel Treeutics帶來了3.1萬美元的銷售額,但損失了87.4萬美元的收益。
Why Is ROCE Significant?
為什麼ROCE意義重大?
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Candel Therapeutics posted an ROCE of -0.07%.
已動用資本回報率是衡量年度税前利潤相對於企業已動用資本的指標。收益和銷售額的變化預示着公司淨資產收益率的變化。較高的淨資產收益率通常代表着一家公司的成功增長,也是未來每股收益更高的標誌。較低的淨資產收益率或負淨資產收益率則表明情況正好相反。在第二季度,Candel Treeutics公佈的淨資產收益率為-0.07%。
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
請記住,雖然淨資產收益率可以很好地衡量一家公司最近的表現,但它並不是一家公司在不久的將來盈利或銷售額的高度可靠的預測指標。
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Candel Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
淨資產收益率是比較類似公司資本配置有效性的有力指標。相對較高的ROCE表明,Candel治療公司可能以比行業內其他公司更高的效率運營。如果公司以目前的資本水平產生高利潤,其中一些資金可以再投資於更多的資本,這通常會帶來更高的回報,並最終實現每股收益(EPS)的增長。
For Candel Therapeutics, a negative ROCE ratio of -0.07% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
對於Candel Treeutics,負的ROCE比率為-0.07%,表明管理層可能沒有有效地配置他們的資本。有效的資本配置是一個積極的指標,表明一家公司將獲得更持久的成功和有利的長期回報;隨着時間的推移,糟糕的資本配置可能會拖累公司的業績。
Upcoming Earnings Estimate
即將到來的收益預期
Candel Therapeutics reported Q2 earnings per share at $-0.3/share, which beat analyst predictions of $-0.41/share.
Candel治療公司公佈第二季度每股收益為-0.3美元,超過了分析師預測的-0.41美元。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自動內容引擎生成,並由編輯審閲。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧